查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1572061

阿加曲班市场：依产品类型、应用、最终用户、治疗领域、给药途径- 2025-2030 年全球预测

Argatroban Market by Product Type (Dosage Strength, Formulations), Application (Percutaneous Coronary Intervention, Treatment Of Heparin-Induced Thrombocytopenia), End-User, Therapeutic Area, Route Of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年阿加曲班市值为6,468万美元，预计2024年将达6,734万美元，预计2030年将达到8,567万美元，复合年增长率为4.09%。

阿加曲班是一种小分子直接凝血酶抑制剂，主要用于抗凝血治疗，特别是肝素诱发的血小板减少性疾病(HIT) 和需要经皮冠状动脉介入治疗的患者。当肝素等传统抗凝血剂无法安全使用时，该药物在预防血栓併发症发挥重要作用，因此需要该药物。其在医学上的应用范围很广泛，延伸到心血管治疗和急诊环境，其中准确的抗凝血管理非常重要。最终用途部分主要是医院、急诊服务和专科诊所，门诊病人设施的兴趣也越来越大。

主要市场统计
基准年[2023] 6468万美元
预测年份 [2024] 6734万美元
预测年份 [2030] 8567万美元
复合年增长率（%） 4.09%

阿加曲班的市场成长是由于心血管疾病盛行率的增加、抗凝血治疗意识的提高以及在医疗基础设施发达的新兴市场扩大应用所推动的。另一个重要因素是它在接受透析的患者中的使用，当传统抗凝血剂构成高风险时，提供了一种替代方案。最近的趋势是透过患者教育和健康专业培训计划扩大该药物在新兴市场的采用。与医疗保健提供者合作提高阿加曲班在 HIT 管理中的有效性可以扩大其市场范围。

然而，高成本、严格的监管要求和潜在副作用等限制限制了更广泛的采用。此外，来自较成熟的抗凝血剂（例如新型口服抗凝血剂（NOAC））的竞争也是一个挑战。透过具有成本效益的製造流程和明确的监管规定来解决这些因素可以加速市场进入和成长。

创新和研发可以在标靶给药系统的开发中蓬勃发展，从而提高阿加曲班的功效和安全性。数位健康工具的出现可以支持个人化治疗方法、优化剂量并减少副作用。总体而言，与製药创新者和技术公司的策略伙伴关係可以为提高阿加曲班的市场地位开闢新途径。儘管市场竞争激烈，但由于持续的研究和开发专注于改善治疗结果和减少不利事件以满足未满足的临床需求，因此它是一个充满前景的市场。

市场动态：揭示快速发展的阿加曲班市场的关键市场洞察

阿加曲班市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 抗凝血剂配方和输送系统的进步提高了阿加曲班的疗效和病人依从性
    • 增加医疗基础设施和抗凝血研究投资，支持阿加曲班市场扩张
    • 对血栓性栓塞症的认识和诊断的提高有助于阿加曲班的市场渗透
    • 主要企业之间的策略伙伴关係和联盟推动阿加曲班市场动态
  • 市场限制因素
    • 阿加曲班的初始成本较高，限制了其在成本敏感市场的可用性；
    • 其他抗凝血剂和新兴治疗方法的竞争
  • 市场机会
    • 由于心血管疾病的增加，对抗凝血治疗的需求不断增加
    • 加大新型抗凝血剂研发投入
    • 新兴国家阿加曲班市场的拓展重点关注医疗改善
  • 市场问题
    • 影响阿加曲班生产过程的原料供应限制和供应链中断
    • 严格的监管核准和合规要求阻碍了阿加曲班产品创新和市场进入

波特五力：驾驭阿加曲班市场的策略工具

波特的五力架构是了解阿加曲班市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解阿加曲班市场的外部影响

外部宏观环境因素在塑造阿加曲班市场的业绩动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解阿加曲班市场的竞争状况

对阿加曲班市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵阿加曲班市场供应商的绩效评估

FPNV定位矩阵是评估Argatroban市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划阿加曲班市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，阿加曲班市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 抗凝血剂配方和输送系统的进步提高了阿加曲班的疗效和病人的依从性
      • 增加医疗基础设施和抗凝血研究投资，推动阿加曲班市场扩张
      • 提高对血栓栓塞性疾病的认识和诊断有助于提高阿加曲班市场渗透率
      • 推动阿加曲班市场动态的主要企业之间的策略伙伴关係和合作
    • 抑制因素
      • 阿加曲班的高初始成本限制了成本敏感市场的可用性
      • 其他抗凝血剂和新治疗方法的竞争
    • 机会
      • 由于心血管疾病的增加，抗凝血治疗的需求增加
      • 加大新型抗凝血剂研发投入
      • 以医疗改善为中心拓展新兴国家阿加曲班市场
    • 任务
      • 原料供应和供应链中断影响阿加曲班生产过程
      • 严格的监管核准和合规要求阻碍了阿加曲班产品创新和市场进入
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章阿加曲班市场：依产品类型

  • 介绍
  • 剂量强度
    • 1mg/mL
    • 2mg/mL
  • 处方
    • 注射液
    • 溶液用粉末

第七章阿加曲班市场：依应用分类

  • 介绍
  • 经皮冠状动脉介入治疗
    • 治疗中
    • 术后护理
  • 肝素诱发的血小板减少性疾病的治疗
    • 急性病例
    • 慢性病例

第八章阿加曲班市场：依最终用户分类

  • 介绍
  • 门诊手术中心
    • 医院相关中心
    • 独立中心
  • 诊所
    • 普通科诊所
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院

第九章阿加曲班市场：依治疗领域

  • 介绍
  • 心臟病学
    • 入侵性心臟病学
    • 无创心臟病学
  • 加护治疗
    • 紧急护理
    • 加护治疗
  • 血液学
    • 血液疾病
    • 凝血病

第 10 章 阿加曲班市场：依给药途径

  • 介绍
  • 心内给药
  • 静脉注射

第十一章 美洲阿加曲班市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太阿加曲班市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲阿加曲班市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 1. Abbvie Inc.
  • 2. AstraZeneca Plc
  • 3. Bayer AG
  • 4. Boehringer Ingelheim GmbH
  • 5. Bristol-Myers Squibb Company
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Eagle Pharmaceuticals Inc.
  • 9. Fresenius Kabi AG
  • 10. GlaxoSmithKline plc (GSK)
  • 11. Hoffmann-La Roche Ltd.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Mitsubishi Tanabe Pharma Corporation
  • 15. Mylan NV
  • 16. Pfizer Inc.
  • 17. Sandoz (a Novartis Division)
  • 18. Sanofi SA
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Teva Pharmaceutical Industries Ltd.
Product Code: MRR-535C62918B41

The Argatroban Market was valued at USD 64.68 million in 2023, expected to reach USD 67.34 million in 2024, and is projected to grow at a CAGR of 4.09%, to USD 85.67 million by 2030.

Argatroban, a small molecule direct thrombin inhibitor, is primarily used for anticoagulation therapy, particularly in patients with heparin-induced thrombocytopenia (HIT) and those requiring percutaneous coronary intervention. The drug's necessity is underscored by its critical role in preventing thrombotic complications where traditional anticoagulants like heparin cannot be used safely. The application scope is wide-ranging within healthcare, extending into cardiovascular treatment and acute care settings, where precise anticoagulation management is crucial. End-use sectors are mainly hospitals, emergency services, and specialty clinics, with a growing interest from outpatient facilities as well.

KEY MARKET STATISTICS
Base Year [2023] USD 64.68 million
Estimated Year [2024] USD 67.34 million
Forecast Year [2030] USD 85.67 million
CAGR (%) 4.09%

Market growth for argatroban is being driven by an increasing incidence of cardiovascular diseases, heightened awareness regarding anticoagulation therapy, and an expansion of its application in emerging markets with improving healthcare infrastructure. Another key factor is its use in patients undergoing dialysis, providing an alternative where traditional anticoagulants pose higher risks. Recent opportunities revolve around expanding the drug's adoption in developing markets through patient education and healthcare professional training programs. Collaborations with healthcare providers to increase the efficacy of argatroban in HIT management could broaden its market scope.

However, limitations such as high cost, stringent regulatory requirements, and the potential for adverse reactions restrict broader adoption. Additionally, competition from more established anticoagulants, such as newer oral anticoagulants (NOACs), poses challenges. Addressing these factors through cost-effective manufacturing processes and clearer regulatory pathways can accelerate market entry and growth.

Innovation and research could thrive in developing targeted drug delivery systems that increase argatroban's efficacy and safety profile. The advent of digital health tools can support personalized treatment approaches, optimizing dosing and reducing adverse reactions. Overall, strategic partnerships with pharmaceutical innovators and technology companies may open new avenues for advancing argatroban's market position. The market nature is competitive yet promising, as ongoing research and development focus on enhancing therapeutic outcomes and reducing adverse events to capitalize on unmet clinical needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Argatroban Market

The Argatroban Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Advancements in anticoagulant formulations and delivery systems improving argatroban efficacy and patient compliance
    • Increasing investment in healthcare infrastructure and anticoagulant research propelling argatroban market expansion
    • Growing awareness and diagnosis of thromboembolic disorders contributing to higher argatroban market penetration
    • Strategic partnerships and collaborations among key players driving argatroban market dynamics
  • Market Restraints
    • High initial cost of argatroban, limiting its accessibility in cost-sensitive markets
    • Competition among other anticoagulants and emerging therapies
  • Market Opportunities
    • Growing demand for anticoagulant therapies due to rise in cardiovascular diseases
    • Increasing investments in research and development for novel anticoagulant drugs
    • Expansion of the argatroban market in emerging economies with a focus on healthcare improvement
  • Market Challenges
    • Limited availability of raw materials and supply chain disruptions affecting argatroban production processes
    • Stringent regulatory approvals and compliance requirements hindering the innovation and market entry of argatroban products

Porter's Five Forces: A Strategic Tool for Navigating the Argatroban Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Argatroban Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Argatroban Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Argatroban Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Argatroban Market

A detailed market share analysis in the Argatroban Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Argatroban Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Argatroban Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Argatroban Market

A strategic analysis of the Argatroban Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Argatroban Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals Inc., Fresenius Kabi AG, GlaxoSmithKline plc (GSK), Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Pfizer Inc., Sandoz (a Novartis Division), Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Argatroban Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Dosage Strength and Formulations. The Dosage Strength is further studied across 1 mg/mL and 2 mg/mL. The Formulations is further studied across Injectable Solutions and Powder For Solution.
  • Based on Application, market is studied across Percutaneous Coronary Intervention and Treatment Of Heparin-Induced Thrombocytopenia. The Percutaneous Coronary Intervention is further studied across During Procedure and Post-Procedure Care. The Treatment Of Heparin-Induced Thrombocytopenia is further studied across Acute Cases and Chronic Cases.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. The Ambulatory Surgical Centers is further studied across Hospital-Associated Centers and Standalone Centers. The Clinics is further studied across General Clinics and Specialized Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Therapeutic Area, market is studied across Cardiology, Critical Care, and Hematology. The Cardiology is further studied across Invasive Cardiology and Non-Invasive Cardiology. The Critical Care is further studied across Emergency Care and Intensive Care. The Hematology is further studied across Blood Disorders and Coagulopathies.
  • Based on Route Of Administration, market is studied across Intracardiac Administration and Intravenous Administration.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Advancements in anticoagulant formulations and delivery systems improving argatroban efficacy and patient compliance
      • 5.1.1.2. Increasing investment in healthcare infrastructure and anticoagulant research propelling argatroban market expansion
      • 5.1.1.3. Growing awareness and diagnosis of thromboembolic disorders contributing to higher argatroban market penetration
      • 5.1.1.4. Strategic partnerships and collaborations among key players driving argatroban market dynamics
    • 5.1.2. Restraints
      • 5.1.2.1. High initial cost of argatroban, limiting its accessibility in cost-sensitive markets
      • 5.1.2.2. Competition among other anticoagulants and emerging therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for anticoagulant therapies due to rise in cardiovascular diseases
      • 5.1.3.2. Increasing investments in research and development for novel anticoagulant drugs
      • 5.1.3.3. Expansion of the argatroban market in emerging economies with a focus on healthcare improvement
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of raw materials and supply chain disruptions affecting argatroban production processes
      • 5.1.4.2. Stringent regulatory approvals and compliance requirements hindering the innovation and market entry of argatroban products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Argatroban Market, by Product Type

  • 6.1. Introduction
  • 6.2. Dosage Strength
    • 6.2.1. 1 mg/mL
    • 6.2.2. 2 mg/mL
  • 6.3. Formulations
    • 6.3.1. Injectable Solutions
    • 6.3.2. Powder For Solution

7. Argatroban Market, by Application

  • 7.1. Introduction
  • 7.2. Percutaneous Coronary Intervention
    • 7.2.1. During Procedure
    • 7.2.2. Post-Procedure Care
  • 7.3. Treatment Of Heparin-Induced Thrombocytopenia
    • 7.3.1. Acute Cases
    • 7.3.2. Chronic Cases

8. Argatroban Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
    • 8.2.1. Hospital-Associated Centers
    • 8.2.2. Standalone Centers
  • 8.3. Clinics
    • 8.3.1. General Clinics
    • 8.3.2. Specialized Clinics
  • 8.4. Hospitals
    • 8.4.1. Private Hospitals
    • 8.4.2. Public Hospitals

9. Argatroban Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiology
    • 9.2.1. Invasive Cardiology
    • 9.2.2. Non-Invasive Cardiology
  • 9.3. Critical Care
    • 9.3.1. Emergency Care
    • 9.3.2. Intensive Care
  • 9.4. Hematology
    • 9.4.1. Blood Disorders
    • 9.4.2. Coagulopathies

10. Argatroban Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intracardiac Administration
  • 10.3. Intravenous Administration

11. Americas Argatroban Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Argatroban Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Argatroban Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. AstraZeneca Plc
  • 3. Bayer AG
  • 4. Boehringer Ingelheim GmbH
  • 5. Bristol-Myers Squibb Company
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Eagle Pharmaceuticals Inc.
  • 9. Fresenius Kabi AG
  • 10. GlaxoSmithKline plc (GSK)
  • 11. Hoffmann-La Roche Ltd.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Mitsubishi Tanabe Pharma Corporation
  • 15. Mylan N.V.
  • 16. Pfizer Inc.
  • 17. Sandoz (a Novartis Division)
  • 18. Sanofi S.A.
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ARGATROBAN MARKET RESEARCH PROCESS
  • FIGURE 2. ARGATROBAN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARGATROBAN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARGATROBAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ARGATROBAN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ARGATROBAN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARGATROBAN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARGATROBAN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARGATROBAN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARGATROBAN MARKET DYNAMICS
  • TABLE 7. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARGATROBAN MARKET SIZE, BY 1 MG/ML, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARGATROBAN MARKET SIZE, BY 2 MG/ML, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARGATROBAN MARKET SIZE, BY FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARGATROBAN MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARGATROBAN MARKET SIZE, BY POWDER FOR SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARGATROBAN MARKET SIZE, BY DURING PROCEDURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARGATROBAN MARKET SIZE, BY POST-PROCEDURE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARGATROBAN MARKET SIZE, BY ACUTE CASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARGATROBAN MARKET SIZE, BY CHRONIC CASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITAL-ASSOCIATED CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARGATROBAN MARKET SIZE, BY STANDALONE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARGATROBAN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARGATROBAN MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARGATROBAN MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARGATROBAN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARGATROBAN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ARGATROBAN MARKET SIZE, BY INVASIVE CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARGATROBAN MARKET SIZE, BY NON-INVASIVE CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ARGATROBAN MARKET SIZE, BY EMERGENCY CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARGATROBAN MARKET SIZE, BY INTENSIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ARGATROBAN MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARGATROBAN MARKET SIZE, BY COAGULOPATHIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ARGATROBAN MARKET SIZE, BY INTRACARDIAC ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARGATROBAN MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED STATES ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED STATES ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 164. AUSTRALIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. AUSTRALIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 168. AUSTRALIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 170. AUSTRALIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 172. AUSTRALIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. AUSTRALIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. AUSTRALIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. CHINA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. CHINA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 179. CHINA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. CHINA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. CHINA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 182. CHINA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. CHINA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 190. CHINA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. INDIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. INDIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 194. INDIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. INDIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. INDIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 197. INDIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 198. INDIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. INDIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 200. INDIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 201. INDIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 202. INDIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 203. INDIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. INDIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 205. INDIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. INDIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. INDONESIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. INDONESIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 209. INDONESIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. INDONESIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. INDONESIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 212. INDONESIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 213. INDONESIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. INDONESIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 215. INDONESIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 216. INDONESIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 217. INDONESIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 218. INDONESIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. INDONESIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 220. INDONESIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. INDONESIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. JAPAN ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. JAPAN ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 224. JAPAN ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. JAPAN ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. JAPAN ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 227. JAPAN ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 228. JAPAN ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. JAPAN ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 230. JAPAN ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 231. JAPAN ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 232. JAPAN ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 233. JAPAN ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. JAPAN ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 235. JAPAN ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. JAPAN ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. MALAYSIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. MALAYSIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 239. MALAYSIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 240. MALAYSIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. MALAYSIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 242. MALAYSIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 243. MALAYSIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. MALAYSIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 245. MALAYSIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 246. MALAYSIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 247. MALAYSIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 248. MALAYSIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. MALAYSIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 250. MALAYSIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. MALAYSIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. PHILIPPINES ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. PHILIPPINES ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 254. PHILIPPINES ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. PHILIPPINES ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. PHILIPPINES ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 258. PHILIPPINES ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 260. PHILIPPINES ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 262. PHILIPPINES ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. PHILIPPINES ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. PHILIPPINES ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 267. SINGAPORE ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. SINGAPORE ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 269. SINGAPORE ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 270. SINGAPORE ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. SINGAPORE ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 272. SINGAPORE ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 273. SINGAPORE ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. SINGAPORE ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 275. SINGAPORE ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 276. SINGAPORE ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 277. SINGAPORE ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 278. SINGAPORE ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. SINGAPORE ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 280. SINGAPORE ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. SINGAPORE ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH KOREA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH KOREA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH KOREA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH KOREA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH KOREA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH KOREA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH KOREA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. SOUTH KOREA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. TAIWAN ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. TAIWAN ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 299. TAIWAN ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. TAIWAN ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. TAIWAN ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 302. TAIWAN ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 303. TAIWAN ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. TAIWAN ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 305. TAIWAN ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 306. TAIWAN ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 307. TAIWAN ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 308. TAIWAN ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. TAIWAN ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 310. TAIWAN ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 311. TAIWAN ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. THAILAND ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. THAILAND ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 314. THAILAND ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 315. THAILAND ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 316. THAILAND ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 317. THAILAND ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 318. THAILAND ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. THAILAND ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 320. THAILAND ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 321. THAILAND ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 322. THAILAND ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 323. THAILAND ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. THAILAND ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 325. THAILAND ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 326. THAILAND ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 327. VIETNAM ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. VIETNAM ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 329. VIETNAM ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 330. VIETNAM ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. VIETNAM ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 332. VIETNAM ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 333. VIETNAM ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 334. VIETNAM ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 335. VIETNAM ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 336. VIETNAM ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 337. VIETNAM ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 338. VIETNAM ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 339. VIETNAM ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 340. VIETNAM ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. VIETNAM ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 344. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 345. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 347. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 348. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 349. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 350. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 351. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 352. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 353. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 354. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 355. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 356. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 357. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 358. DENMARK ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 359. DENMARK ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 360. DENMARK ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 361. DENMARK ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 362. DENMARK ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONA